Looks like Carl Icahn wasn’t kidding when he said he had a mystery bidder prepared to acquire ImClone at $70 a share. The Wall Street Journal is reporting that Eli Lilly is looking at purchasing ImClone for $6.1 billion.
Bristol-Meyers Squibb has pursued ImClone for the past few months to no avail. Intially they offered $60 a share for the company, then they bumped it to $62. If they intend to start a bidding war with Eli Lilly, they better start soon, as ImClone said on Monday it wanted to close its deal with Eli Lilly by midnight on Wednesday.
NOW WATCH: Briefing videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.